We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05062980
Title Reqorsa (Quaratusugene Ozeplasmid) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2)
Acronym Acclaim-2
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Center - Magnolia Campus Tampa Florida 33612 United States Details
Ochsner Clinic Foundation New Orleans Louisiana 70121 United States Details
Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri 63110 United States Details
The Valley Hospital - Luckow Pavilion Paramus New Jersey 07652 United States Details
Mary Crowley Cancer Research Dallas Texas 75230 United States Details
Millennium Oncology Houston Texas 77090 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field